Welcome to our dedicated page for Vaxcyte news (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.
Vaxcyte, Inc. (PCVX) is a clinical-stage biopharmaceutical leader developing next-generation vaccines against invasive bacterial diseases. This page provides investors and stakeholders with timely updates on corporate developments, clinical trial progress, and regulatory milestones.
Access official press releases and verified news covering Vaxcyte's innovative pipeline, including its VAX-24 and VAX-31 pneumococcal conjugate vaccine candidates engineered using the proprietary XpressCF™ platform. Stay informed about advancements in broad-spectrum protection strategies targeting pneumococcal disease and other bacterial infections.
Key content categories include clinical trial results, manufacturing partnerships, intellectual property updates, and scientific presentations. All materials are sourced directly from company filings and accredited industry publications to ensure accuracy.
Bookmark this page for streamlined access to essential updates about Vaxcyte's mission to redefine vaccine development through advanced synthetic biology and carrier-sparing conjugate technologies.
Vaxcyte (Nasdaq: PCVX) announced a webcast and conference call on September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1/2 study of VAX-31, their 31-valent pneumococcal conjugate vaccine (PCV) candidate. The study evaluated the safety, tolerability, and immunogenicity of VAX-31 in healthy adults aged 50 and older. VAX-31 is designed to prevent invasive pneumococcal disease (IPD). Interested parties can participate via phone (800-225-9448 domestic, 203-518-9708 international) using conference ID PCVX0903 or through a live webcast on Vaxcyte's investor relations page. The webcast will be archived for 30 days after the event.
Vaxcyte (PCVX) reported Q2 2024 financial results and provided a business update. Key highlights include:
- VAX-31 adult Phase 1/2 study topline data expected in September 2024
- VAX-24 infant Phase 2 study topline data expected by Q1 2025
- $1.9 billion in cash and investments as of June 30, 2024
- R&D expenses increased to $131.5 million in Q2 2024
- Net loss widened to $128.7 million in Q2 2024
The company plans to advance either VAX-24 or VAX-31 to Phase 3 in adults following the VAX-31 data readout. Vaxcyte also appointed John Furey to its Board of Directors and received a $9.5 million NIAID grant for Chlamydia vaccine development.
Vaxcyte has appointed John Furey to its Board of Directors, effective July 2, 2024. Furey brings extensive experience in the biopharmaceutical and vaccine sectors, especially in the manufacture, supply, and commercialization of pneumococcal conjugate vaccines (PCVs). This addition comes as Vaxcyte advances its PCV candidates, VAX-24 and VAX-31, towards late-stage clinical development. Furey's expertise is expected to provide strategic insights and strengthen the company’s efforts in developing innovative vaccines using a cell-free technology platform.
Vaxcyte, Inc. (Nasdaq: PCVX) reported Q1 2024 financial results, highlighting completion of enrollment for VAX-31 Adult Phase 1/2 study and VAX-24 Infant Phase 2 study. They expect data by Q3 2024 and Q1 2025 respectively. The company had $1.9 billion in cash as of March 31, 2024, following a successful $816.5 million public offering in February. The company is progressing its PCV franchise and early-stage pipeline, focusing on preventing bacterial diseases.
FAQ
What is the current stock price of Vaxcyte (PCVX)?
What is the market cap of Vaxcyte (PCVX)?
